Clinical review report: Latanoprostene bunod (Vyzulta) (Bausch Health Canada Inc.)
The objective of this review was to perform a systematic review of the beneficial and harmful effects of latanoprostene bunod 0.024% ophthalmic solution for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
August 2019, 2019
|
| Edition: | Version: final (with redactions) |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review was to perform a systematic review of the beneficial and harmful effects of latanoprostene bunod 0.024% ophthalmic solution for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension |
|---|---|
| Physical Description: | 1 PDF file (98 pages) illustrations |